We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation.
- Authors
Fujisaka, Y; Sugiyama, T; Saito, H; Nagase, S; Kudoh, S; Endo, M; Sakai, H; Ohashi, Y; Saijo, N
- Abstract
Erythropoietin-stimulating agents (ESAs) effectively decrease the transfusion requirements of patients with chemotherapy-induced anaemia (CIA). Recent studies indicate that ESAs increase mortality and accelerate tumour progression. The studies also identify a 1.6-fold increased risk of venous thromboembolism. The ESA labelling was thus revised in Europe and the United States in 2008. This is the first randomised, phase III trial evaluating the efficacy and safety of epoetin-β (EPO), an ESA, dosed in accordance with the revised labelling, which specifies that ESAs should be administered to CIA patients with a haemoglobin level of ≤ 10 g dl⁻¹ and that a sustained haemoglobin level of > 12 g dl⁻¹ should be avoided.
- Publication
British journal of cancer, 2011, Vol 105, Issue 9, p1267
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/bjc.2011.395